1. Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure

   • Paul Cornes
   • Pere Gascon
   • Matti Aapro

   Current Opinion Open access 30 March 2020 Pages: 255 - 263

   

2. Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies

   • Luigia Rossi
   • Francesca Pierigè
   • Mauro Magnani

   Leading Article Open access 20 March 2020 Pages: 265 - 272

3. In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

   • Ami Patel
   • Mamadou A. Bah
   • David B. Weiner

   Leading Article Open access 10 March 2020 Pages: 273 - 293

   

4. Correction to: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies

   • Ami Patel
   • Mamadou A. Bah
   • David B. Weiner

   Correction Open access 02 April 2020 Pages: 295 - 295

5. The Path Towards a Tailored Clinical Biosimilar Development

   • Martin Schiestl
   • Gopinath Ranganna
   • Julie Maréchal-Jamil

   Review Article Open access 07 April 2020 Pages: 297 - 306

   

6. Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status

   • Alice Mariottini
   • Eleonora De Matteis
   • Paolo A. Muraro

   Review Article 12 March 2020 Pages: 307 - 325

   

7. Cell-Free Protein Synthesis: A Promising Option for Future Drug Development

   • Srujan Kumar Dondapati
   • Marlitt Stech
   • Stefan Kubick

   Review Article Open access 20 March 2020 Pages: 327 - 348

   

8. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma

   • Daniel R. Almquist
   • Daniel H. Ahn
   • Tanios S. Bekaii-Saab

   Review Article 03 April 2020 Pages: 349 - 362

   

9. Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin^® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology

   • Liqi Xie
   • Erhui Zhang
   • Scott Liu

   Original Research Article Open access 18 February 2020 Pages: 363 - 379

   

10. Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial

    • Jinmei Su
    • Mengtao Li
    • Xiaofeng Zeng

    Original Research Article Open access 20 February 2020 Pages: 381 - 393

    

11. Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study

    • Stephanie L. Ho
    • Fang Niu
    • Rita L. Hui

    Original Research Article Open access 26 February 2020 Pages: 395 - 404

    

12. Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study

    • Stephanie L. Ho
    • Fang Niu
    • Rita L. Hui

    Correction Open access 06 April 2020 Pages: 405 - 405